pyrimethamine has been researched along with B-Cell Chronic Lymphocytic Leukemia in 2 studies
Maloprim: contains above 2 cpds
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JR | 1 |
| Walker, SR | 1 |
| Heppler, LN | 1 |
| Tyekucheva, S | 1 |
| Nelson, EA | 1 |
| Klitgaard, J | 1 |
| Nicolais, M | 1 |
| Kroll, Y | 1 |
| Xiang, M | 1 |
| Yeh, JE | 1 |
| Chaudhury, M | 1 |
| Giaccone, ZT | 1 |
| Fernandes, SM | 1 |
| Jacobsen, ED | 1 |
| Fisher, DC | 1 |
| Freedman, AS | 1 |
| Davids, MS | 1 |
| Supko, JG | 1 |
| Wu, C | 1 |
| Frank, DA | 1 |
| Marzolini, MAV | 1 |
| Jaunmuktane, Z | 1 |
| Roddie, C | 1 |
| O'Reilly, M | 1 |
| Chiodini, P | 1 |
| Peggs, KS | 1 |
1 trial available for pyrimethamine and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; B-Lymphocytes; Cell Line, Tumor; Dose-Respons | 2021 |
1 other study available for pyrimethamine and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Toxoplasmosis initially presenting as neurological sequelae of chimeric antigen receptor T-cell therapy.
Topics: Cognitive Dysfunction; Humans; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Male | 2019 |